These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17998153)

  • 1. Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?
    Clarke J; Hurst C; Martin P; Vahle J; Ponce R; Mounho B; Heidel S; Andrews L; Reynolds T; Cavagnaro J
    Regul Toxicol Pharmacol; 2008 Feb; 50(1):2-22. PubMed ID: 17998153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Juvenile animal toxicity study designs to support pediatric drug development.
    Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance of the toxicity of pharmaceuticals in humans and in animals.
    Olson H; Betton G; Robinson D; Thomas K; Monro A; Kolaja G; Lilly P; Sanders J; Sipes G; Bracken W; Dorato M; Van Deun K; Smith P; Berger B; Heller A
    Regul Toxicol Pharmacol; 2000 Aug; 32(1):56-67. PubMed ID: 11029269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products.
    Lewis RM; Cavagnaro J
    Biologicals; 2010 Jul; 38(4):494-500. PubMed ID: 20359910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amended final report on the safety assessment of glyceryl dilaurate, glyceryl diarachidate, glyceryl dibehenate, glyceryl dierucate, glyceryl dihydroxystearate, glyceryl diisopalmitate, glyceryl diisostearate, glyceryl dilinoleate, glyceryl dimyristate, glyceryl dioleate, glyceryl diricinoleate, glyceryl dipalmitate, glyceryl dipalmitoleate, glyceryl distearate, glyceryl palmitate lactate, glyceryl stearate citrate, glyceryl stearate lactate, and glyceryl stearate succinate.
    Int J Toxicol; 2007; 26 Suppl 3():1-30. PubMed ID: 18273450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Veterinary pharmacovigilance. Part 6. Predictability of adverse reactions in animals from laboratory toxicology studies.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):213-31. PubMed ID: 15842309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products.
    Int J Toxicol; 2008; 27 Suppl 4():1-82. PubMed ID: 19101832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations.
    Vahle JL; Finch GL; Heidel SM; Hovland DN; Ivens I; Parker S; Ponce RA; Sachs C; Steigerwalt R; Short B; Todd MD
    Toxicol Pathol; 2010 Jun; 38(4):522-53. PubMed ID: 20472697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative hepatic toxicity: prechronic/chronic liver toxicity in rodents.
    Hardisty JF; Brix AE
    Toxicol Pathol; 2005; 33(1):35-40. PubMed ID: 15805054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical aspects regarding the application of GPL principles to new compounds such as biotechnology products.
    Brunetti MM
    Ann Ist Super Sanita; 2008; 44(4):385-9. PubMed ID: 19352001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
    Stevens JL
    Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do preclinical testing strategies help predict human hepatotoxic potentials?
    Peters TS
    Toxicol Pathol; 2005; 33(1):146-54. PubMed ID: 15805066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final report of the safety assessment of Alcohol Denat., including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C, and the denaturants, Quassin, Brucine Sulfate/Brucine, and Denatonium Benzoate.
    Cosmetic Ingredient Review Expert Panel
    Int J Toxicol; 2008; 27 Suppl 1():1-43. PubMed ID: 18569160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.